Elabela: Physiology and What Research Reports
Elabela (ELA, also written ELABELA or Apela) is an endogenous peptide that acts as a second ligand for the apelin receptor. Most of what is known comes from cell and rodent work, where researchers reported effects on heart development, cardiac remodelling, vascular tone, vascular calcification, atherosclerotic plaque macrophages, liver ischaemia-reperfusion injury and uric acid handling. Human data are largely observational, measuring circulating Elabela concentrations in pregnancy cohorts. No human efficacy trials appear in the literature summarised here.
Elabela — written variously as ELA, ELABELA or Apela — is a short endogenous peptide that binds the apelin receptor (APJ/APLNR). It was identified after apelin and is generally described as the receptor's second, developmentally earlier ligand. Because it shares a receptor with apelin but has its own expression pattern and processing, it appears frequently in cardiovascular, renal and developmental physiology literature, and readers encountering the term in peptide discussions usually meet it there first. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question. It summarises published findings and does not describe how any substance is used.
What Elabela Is
Elabela is produced from a precursor protein and circulates as shorter processed fragments. It is characterised in the literature as an endogenous signalling peptide rather than a synthetic analogue — a 2025 mouse study described it explicitly as "an endogenous peptide" when examining its role in uric acid metabolism (PMID 41067286). Its biological interest comes from the apelinergic system, a signalling axis involved in cardiovascular tone, fluid balance and embryonic patterning.
Where it is studied in the body
- Heart and cardiac development — a 2026 study reported that ELABELA targets mitochondria to modulate heart development (PMID 41944334).
- Vessel wall — work in thoracic aortic dissection models reported effects on vascular smooth muscle cell homeostasis and NETosis (PMID 41783930).
- Airway and pulmonary vasculature — a 2023 ex vivo study reported relaxation of rat pulmonary artery and trachea (PMID 37059294).
- Liver and remote organs — a 2025 rat study examined hepatic ischaemia/reperfusion injury (PMID 40679610).
- Pregnancy — circulating Elabela has been measured in maternal blood in several clinical cohorts (PMID 35315019).
What the Cardiovascular Literature Reports
The largest cluster of Elabela research is cardiovascular. In hypertensive mice, researchers reported that Elabela alleviated ferroptosis, myocardial remodelling, fibrosis and heart dysfunction, and linked the effect to IL-6/STAT3/GPX4 signalling (PMID 35122997). In a myocardial ischaemia–reperfusion model, the study reported reductions in apoptosis, fibrosis and mitochondrial dysfunction through PI3K/AKT signalling (PMID 32913520).
Atherosclerosis has also been examined: a 2025 report in ApoE-deficient mice described amelioration of atherosclerosis attributed to restoration of the M1/M2 macrophage balance (PMID 40654251). A separate line of work reported that Elabela alleviated cuproptosis and vascular calcification in vitamin D3-overloaded mice via PPAR-γ/FDX1 signalling (PMID 39567863). Together these reports position Elabela as a signalling molecule studied for vascular and myocardial protection in disease models — not as an established therapy.
Engineering for stability
Short endogenous peptides are typically cleared quickly, which limits experimental use. One approach appearing in the literature is fusion to an immunoglobulin Fc domain: a 2025 mouse study of Fc-Elabela reported mitigation of heart failure without liver and renal toxicity (PMID 40727092). This illustrates why half-life engineering is a recurring theme in apelinergic research.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeBeyond the Heart: Other Reported Roles
A 2025 rat study reported that Elabela alleviated ischemia/reperfusion-induced hepatic and remote organ injury by inhibiting oxidative stress (PMID 40679610). In metabolic research, a 2025 mouse study reported amelioration of hyperuricaemia through inhibition of uric acid production via CYP27A1-modulated bile acid metabolism (PMID 41067286). Smooth-muscle pharmacology adds mechanistic detail: researchers reported that Elabela relaxed rat pulmonary artery and trachea via BK(Ca), K(V) and K(ATP) potassium channels (PMID 37059294).
How Elabela Is Measured and Studied
Two broad approaches dominate:
- Interventional animal and cell work. Synthetic Elabela, or a modified form, is administered to rodents or applied to cultured cells, and outcomes such as fibrosis, apoptosis, calcification or macrophage phenotype are measured against controls — the pattern used in the atherosclerosis (PMID 40654251) and vascular calcification (PMID 39567863) studies.
- Observational human measurement. Circulating Elabela is quantified by immunoassay and compared between clinical groups. Researchers reported differences in Elabela levels in pregnancies complicated by intrauterine growth retardation (PMID 35315019), and a separate cohort examined circulating Elabela in pregnant women with missed abortion (PMID 35758889).
Observational measurement cannot establish cause and effect; it describes association only. Interventional rodent findings, likewise, do not transfer automatically to humans.
| Research area | Model | Reported finding |
|---|---|---|
| Heart development | Developmental model | ELABELA targeted mitochondria to modulate heart development (PMID 41944334) |
| Hypertensive heart disease | Mice | Alleviated ferroptosis, fibrosis and heart dysfunction via IL-6/STAT3/GPX4 (PMID 35122997) |
| Aortic dissection | Vascular model | Maintained smooth muscle cell homeostasis and regulated NETosis (PMID 41783930) |
| Heart failure | Mice, Fc-fusion | Mitigated heart failure without liver and renal toxicity (PMID 40727092) |
| Pregnancy biomarker | Human cohort | Levels measured in pregnancies with intrauterine growth retardation (PMID 35315019) |
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appElabela Tolerability: What Studies Report
Published safety information is limited and comes from animal work rather than human trials. The Fc-Elabela heart failure study reported that the fusion peptide mitigated heart failure in mice without liver and renal toxicity (PMID 40727092). Other reports focused on efficacy endpoints such as oxidative stress markers in rats rather than systematic toxicology (PMID 40679610). Absence of reported toxicity in a single rodent study is not evidence of human safety, and no human efficacy or safety trial of administered Elabela appears among the studies summarised here.
Why the Term Matters in Peptide Research
Elabela is often encountered as a research-use-only laboratory peptide and as a biomarker name in clinical papers. It is not an approved drug product in the United States, and the findings above describe experimental models. Readers meeting the term should note the gap between mechanistic rodent findings — mitochondrial, macrophage, potassium-channel and ferroptosis pathways — and any clinical conclusion. The literature at present supports scientific interest in the apelinergic system, not established human outcomes.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeKey Limitations of the Current Evidence
- Most interventional evidence is rodent or cell-based, including the atherosclerosis (PMID 40654251) and hyperuricaemia (PMID 41067286) reports.
- Human data are observational biomarker studies in pregnancy cohorts (PMID 35758889).
- Assay methods for circulating Elabela differ between laboratories, complicating comparison across cohorts (PMID 35315019).
- Peptide stability remains a practical constraint, which is why fusion constructs have been tested (PMID 40727092).
References
- ELABELA Ameliorates Atherosclerosis Through Restoring the M1/M2 Macrophage Balance in ApoE(-/-) Mice (Journal of the American Heart Association, 2025)
- Elabela alleviates ischemia/reperfusion-induced hepatic and remote organ injury by inhibiting oxidative stress in rats (Pflugers Archiv, 2025)
- Elabela relaxes rat pulmonary artery and trachea via BK(Ca), K(V), and K(ATP) channels (Prostaglandins & Other Lipid Mediators, 2023)
- Elabela alleviates cuproptosis and vascular calcification in vitaminD3-overloaded mice via regulation of the PPAR-γ/FDX1 signaling (Molecular Medicine, 2024)
- Elabela alleviates ferroptosis, myocardial remodeling, fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6/STAT3/GPX4 signaling (Free Radical Biology & Medicine, 2022)
- Roles of an endogenous peptide ELABELA in ameliorating hyperuricemia by inhibiting uric acid production via CYP27A1-modulated bile acid metabolism in mice (Biochemical Pharmacology, 2025)
- Elabela levels in pregnancies with intrauterine growth retardation (Ginekologia Polska, 2023)
- Circulating levels of Elabela in pregnant women with missed abortion (Gynecological Endocrinology, 2022)
- Elabela alleviates myocardial ischemia reperfusion-induced apoptosis, fibrosis and mitochondrial dysfunction through PI3K/AKT signaling (American Journal of Translational Research, 2020)
- ELABELA Targets Mitochondria to Modulate Heart Development (Advanced Science, 2026)
- ELABELA Protects Against Thoracic Aortic Dissection by Maintaining Vascular Smooth Muscle Cells Homeostasis and Regulating NETosis (Arteriosclerosis, Thrombosis, and Vascular Biology, 2026)
- Fc-Elabela mitigates heart failure without liver and renal toxicity in mice (Frontiers in Pharmacology, 2025)
Frequently asked questions
What is Elabela?▾
Elabela, also written ELABELA or Apela, is an endogenous peptide that signals through the apelin receptor. A 2025 mouse study described it as an endogenous peptide while examining hyperuricaemia and bile acid metabolism (PMID 41067286). Most published work is mechanistic, using cell and rodent models rather than human interventional trials, so its physiological role is still being mapped.
What has Elabela research reported about the heart?▾
In hypertensive mice, researchers reported that Elabela alleviated ferroptosis, myocardial remodelling, fibrosis and heart dysfunction through IL-6/STAT3/GPX4 signalling (PMID 35122997). A myocardial ischaemia–reperfusion study reported reduced apoptosis, fibrosis and mitochondrial dysfunction via PI3K/AKT signalling (PMID 32913520). A 2026 report described ELABELA targeting mitochondria to modulate heart development (PMID 41944334).
Has Elabela been studied in blood vessels?▾
Yes. A 2025 study in ApoE-deficient mice reported amelioration of atherosclerosis linked to restoring the M1/M2 macrophage balance (PMID 40654251). Another reported reduced cuproptosis and vascular calcification in vitamin D3-overloaded mice via PPAR-γ/FDX1 signalling (PMID 39567863). A 2026 study reported protection against thoracic aortic dissection through smooth muscle cell homeostasis and NETosis regulation (PMID 41783930).
How is Elabela measured in humans?▾
Human work is observational, using immunoassays to compare circulating concentrations between groups. Researchers measured Elabela levels in pregnancies complicated by intrauterine growth retardation (PMID 35315019), and a separate cohort examined circulating Elabela in pregnant women with missed abortion (PMID 35758889). Such association studies describe differences between groups; they cannot establish that the peptide causes the outcome.
What do studies report about Elabela tolerability?▾
Published tolerability information comes from animals, not human trials. A 2025 mouse study of an Fc-fusion construct reported that Fc-Elabela mitigated heart failure without liver and renal toxicity (PMID 40727092). Other reports focused on efficacy endpoints such as oxidative stress in rats rather than systematic toxicology (PMID 40679610). Human safety data are absent from the literature summarised here.
Why is Elabela sometimes engineered as a fusion peptide?▾
Short peptides are cleared rapidly, which limits experimental durability. Researchers therefore tested an immunoglobulin Fc-fused version, and the study reported that Fc-Elabela mitigated heart failure in mice without liver and renal toxicity (PMID 40727092). Half-life extension is a common strategy across apelinergic research and explains why several Elabela constructs appear in the literature.
Does Elabela affect smooth muscle directly?▾
A 2023 study reported that Elabela relaxed rat pulmonary artery and trachea, and attributed the response to BK(Ca), K(V) and K(ATP) potassium channels (PMID 37059294). These were isolated tissue experiments, so the findings describe pharmacological mechanism in rat tissue rather than demonstrated respiratory or pulmonary vascular effects in people.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.